Propanc Biopharma (NASDAQ:PPCB) Posts Earnings Results

Propanc Biopharma (NASDAQ:PPCB) issued its quarterly earnings data on Friday. The company reported ($12.22) EPS for the quarter, FiscalAI reports.

Propanc Biopharma Stock Down 0.3%

Shares of PPCB stock traded down $0.01 during trading on Friday, reaching $1.92. The company’s stock had a trading volume of 9,280 shares, compared to its average volume of 171,484. Propanc Biopharma has a one year low of $1.63 and a one year high of $315.00. The business has a fifty day moving average price of $4.73 and a 200-day moving average price of $20.69. The company has a market cap of $1.21 million, a price-to-earnings ratio of -0.01 and a beta of 3.55.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Propanc Biopharma Company Profile

Propanc Biopharma, Inc. (NASDAQ:PPCB) is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors, including pancreatic, ovarian and colorectal cancers. The company’s research is based on proenzyme therapy, an approach intended to selectively target cancer cells and cancer stem cells while limiting tumor growth, recurrence and metastasis. Propanc’s lead investigational product is PRP, also referred to as PRP-100, an intravenous formulation comprising the naturally occurring digestive proenzymes trypsinogen and chymotrypsinogen.